On March 2, 2021 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, reported a partnership with leading health system Providence to advance the science and delivery of cancer care (Press release, Grail, MAR 2, 2021, View Source [SID1234575968]). Providence, based in Renton, Washington, will be the first health system to offer Galleri, GRAIL’s multi-cancer early detection blood test, as a complement to recommended single cancer screening tests.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Galleri test initially will be used by Providence at its California, Washington, and Oregon points of care, and could eventually be available across Providence’s entire seven-state footprint that includes more than 50 hospitals and nearly 1,100 health clinics serving 5 million patients. Providence aims to pursue effective ways to identify cancer earlier in patient lives, and will integrate the Galleri test into clinical care to help drive earlier detection of multiple cancers and to try to improve and save lives.
"Today, the majority of cancers are found too late when outcomes are often fatal, and as a result, cancer is projected to become the leading cause of death worldwide," said Hans Bishop, chief executive officer at GRAIL. "Providence is a leading health system that shares our commitment to improving and saving lives, and our partnership moves us that much closer to making a tremendous and potentially life-altering difference for patients and providers. We are encouraged by interest in Galleri from health systems, medical practices, and self-insured employers, and excited by the progress in our mission to detect cancer early."
"At Providence, we continuously strive to deliver the most innovative medical advances to our patients, and we are thrilled to partner with GRAIL on implementation research that may bring Galleri to all the communities we serve," said Amy Compton-Phillips, MD, chief clinical officer at Providence. "When combined with the power of our genomics research, having a single blood test that can detect more than 50 cancers advances our goal of finding cancer early, enabling our providers to administer treatment when it’s most likely to be successful and giving our patients the opportunity to achieve the best possible outcomes."
GRAIL previously announced it expects to introduce Galleri in the second quarter of 2021. The blood test, which will be prescription only, will be available initially through partner health systems, medical practices, and self-insured employers.
An earlier version of Galleri demonstrated the ability to detect more than 50 types of cancers — over 45 of which lack recommended screening tests today — with a low false positive rate of less than 1%. When a cancer signal is detected, Galleri can determine where in the body the cancer is located with high accuracy, all from a single blood draw.